ALNY · Alnylam Pharmaceuticals
AI read · Bad for ALNY
The AI's read
The lower target shows Truist now sees less room for Alnylam's shares to rise. The buyback could support shareholders, but it does not erase the firm's lower rating and target.
Truist Securities changed Alnylam Pharmaceuticals' rating from Buy to Hold and cut its price target.
Bad for ALNY
Truist lowered its rating and share-price target for Alnylam, signaling a less favorable view. The $1 billion buyback authorization is supportive, but does not cancel out that negative signal.
Get alerts for ALNY
Follow Alnylam Pharmaceuticals (ALNY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ALNYFree on the App Store and Google Play, or on the web.